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Cell-cell adhesion is a dynamic process that can activate mul-
tiple signaling pathways. These signaling pathways can be regu-
lated through reversible tyrosine phosphorylation events. The
level of tyrosine phosphorylation of junctional proteins reflects
the balance between protein-tyrosine kinase and protein-tyro-
sine phosphatase activity. The receptor-tyrosine phosphatase
DEP-1 (CD148/PTP-) has been implicated in cell growth and
differentiation as well as in regulating phosphorylation of junc-
tional proteins. However, the role of DEP-1 in regulating tight
junction phosphorylation and the integrity of cell-cell junctions
is still under investigation. In this study, we used a catalytically
dead substrate-trapping mutant of DEP-1 to identify potential
substrates at cell-cell junctions. We have shown that in epithe-
lial cells the trapping mutant of DEP-1 interacts with the tight
junction proteins occludin and ZO-1 in a tyrosine phosphoryl-
ation-dependent manner. In contrast, PTP-PEST, Shp2, and
PTP did not interact with these proteins, suggesting that the
interaction ofDEP-1with occludin andZO-1 is specific. In addi-
tion, occludin and ZO-1 were dephosphorylated by DEP-1 but
not these other phosphatases in vitro. Overexpression of DEP-1
increased barrier function as measured by transepithelial elec-
trical resistance and also reducedparacellular flux of fluorescein
isothiocyanate-dextran following a calcium switch. Reduced
DEP-1 expression by small interfering RNA had a small but sig-
nificant increase in junction permeability. These data suggest
that DEP-1 can modify the phosphorylation state of tight junc-
tion proteins and play a role in regulating permeability.
Tight junctions are the most apical of junctions formed by
epithelia and provide a regulated barrier to paracellular trans-
port of ions, solutes, macromolecules, and even other cells. In
addition, tight junctions act as a “fence” within the plane of the
membrane, dividing the apical and basolateral domains of
polarized epithelial cells. These junctions play an important
role in the regulation of multiple cellular processes including
cell differentiation, proliferation, and polarity (for reviews see
Refs. 1 and 2). Functional tight junctions are characterized by
the presence of membrane spanning proteins (claudins, occlu-
din, and JAMs), which interact with cytoplasmic proteins (AF-6
andZO-1, -2, -3), regulating assembly andmaintenance of tight
junctions. Occludin spans the membrane four times and was
the first transmembrane component of the tight junction to be
identified (3). It has two extracellular regions, an intracellular
loop, as well as both an N- and C-terminal cytoplasmic tail (3).
The C-terminal tail of occludin binds directly to the ZO family
of proteins, which link the protein complex to the actin
cytoskeleton (4–8). The long C-terminal domain is rich in ser-
ine, threonine, and tyrosine residues (9). In fact, several kinases
and phosphatases interact with and modulate the phosphoryl-
ation state of tight junction proteins (10–14). Serine and thre-
onine phosphorylation of occludin is abundant in epithelia with
intact junctions, whereas tyrosine phosphorylation is undetect-
able (15). However, tyrosine phosphorylation of occludin is
associated with a decrease in transepithelial electrical resist-
ance (TER)2 (16, 17) and loss of protein localization at the tight
junction (18). Increases in tyrosine phosphorylation of occludin
and ZO-1 result in the dissociation of the occludin-ZO-1 com-
plex and reduces the localization at the tight junction of these
proteins (12, 19). These data suggest that the phosphorylation
state of tight junction proteins can affect the integrity of the
tight junction complex and therefore the integrity of the tight
junction itself. Both serine and threonine kinases and phospha-
tases bind to and act on TJ proteins (reviewed in Ref. 20). Pre-
vious studies have identified that c-Src and c-Yes are protein-
tyrosine kinases, which act on the TJ, however, to date no
protein-tyrosine phosphatases have been specifically charac-
terized as acting on TJ proteins (11–13, 21).
Similarly, the other major junction of epithelia, the adherens
junction (AJ), is also regulated by tyrosine phosphorylation.
Increased tyrosine phosphorylation of the AJ decreases the sta-
bility of the cadherin-catenin complex, disrupting the associa-
tion with the cytoskeleton and reducing junctional integrity
(22–24). Therefore, these studies suggest that maintenance of
junctional integrity for both theTJ andAJ is regulated in part by
reversible tyrosine phosphorylation that results from a compet-
ing balance of protein-tyrosine kinase and protein-tyrosine
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phosphatase (PTP) activity. Several PTPs have been localized to
AJs and shown to bind components of the cadherin-catenin
complex. The PTPs in AJs include receptor-PTPs (PTP,
DEP-1, and vascular endothelial-PTP), as well as cytosolic PTPs
(PTP1B and Shp-2) (25–30). The high concentration of PTPs at
cell-cell junctions indicates the importance of maintaining low
levels of tyrosine phosphorylation except when the junctions
need to be remodeled or disassembled.
DEP-1 (density-enhanced phosphatase-1) is a receptor PTP
that was first cloned from a human cDNA library and named
based on the observation that its expression was elevated with
increasing cell density (31). Also known as PTP-, PTPRJ, and
CD148, DEP-1 is comprised of an extracellular domain of eight
fibronectin type III repeats, a transmembrane domain, and a
single cytoplasmic catalytic domain. The protein is ubiqui-
tously expressed (32), indicating its potential involvement in a
large number of diverse signaling pathways. DEP-1 is involved
in regulating the differentiation of epithelial cells (33–36), as
well as controlling cell growth and adhesion (33, 34). In addi-
tion, DEP-1 is able to attenuate the cellular response to growth
factors through the preferential dephosphorylation of several
growth factor receptors, suggesting that DEP-1 can selectively
dephosphorylate certain tyrosines to more finely control sig-
naling (37–41).
In addition to its role in proliferation and differentiation,
DEP-1 localizes to areas of cell-cell adhesion in endothelial and
epithelial cells, overlapping with the AJ marker vascular endo-
thelial-cadherin in endothelia (42). Interaction with p120 cate-
nin as well as othermembers of the catenin family also supports
the hypothesis that DEP-1 plays a role in regulating AJ protein
phosphorylation (27, 40). In the current study, we investigated
whether adjacent tight junction proteins are also substrates of
DEP-1. We now demonstrate that the substrate-trapping
mutant of DEP-1 interacts with the tight junction proteins
occludin and ZO-1. The association of DEP-1 with occludin
and ZO-1 is specific to DEP-1 and not other phosphatases
tested. In addition, DEP-1 is able to dephosphorylate occludin
and ZO-1 indicating that these tight junction proteins are sub-
strates of DEP-1. Furthermore, increased expression of DEP-1
enhances barrier function as junctions reform following a cal-
cium switch and loss of DEP-1 levels increased the permeability
of a stable epithelial monolayer. Together these results indicate
that ZO-1 andoccludin are substrates ofDEP-1 and imply a role
for DEP-1 in influencing the phosphorylation state of tight
junction proteins and junction permeability.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfections
MCF10A cells were grown in a 1:1 mixture of Dulbecco’s
modified Eagle’s medium (DMEM) and Ham’s F-12 medium
supplemented with 5% horse serum, 20 ng/ml epidermal
growth factor (EGF), 0.01 mg/ml insulin, 500 ng/ml hydrocor-
tisone, 100 ng/ml cholera toxin and antibiotics. MDCK II,
A431, and HEK 293 cells were cultured in Dulbecco’s modified
Eagle’s medium-high glucose enriched with 10% fetal bovine
serum and antibiotics. Cells were transfected with Lipo-
fectamine 2000 (Invitrogen) or FuGENE 6 (Roche Applied Sci-
ence) according to themanufacturer’s instructions. RNA inter-
ference oligos were transfected using TransIT-siQUEST
(Mirus).
Constructs and Antibodies
pMT2DEP-1WT, pMT2DEP-1D/A, and pMT2DEP-1 C/S
(GenBankTM accession number U10886) were kindly provided
by Nicholas Tonks (Cold Spring Harbor Laboratory). GFP
DEP-1 WT was generated by subcloning the pMT2 construct
into pEGFP-N2 (Clontech). DEP-1 cytoplasmic domain con-
structs were generated using the pMT2 DEP-1 wild type,
D1205A, or C1239S point mutants as templates. A 5 primer
introduced an EcoRI site before the DEP-1 cytoplasmic
sequence at nucleotide 3338 and a 3 primer introduced a XhoI
site after the DEP-1 stop codon. The resulting PCR fragments
(nucleotides 3338–4362) were cloned into the EcoRI/XhoI
sites of the pGEX-4T-1 vector (GEHealthcare), creating wild
type and point mutants D1205A and C1239S pGEX-DEP-1
constructs. GST-PTP-PEST wild type and the substrate-
trapping mutant were obtained from Dr. Sarita Sastry (Uni-
versity of Texas, Galveston, TX), and GST-PTP wild type
and substrate-trapping mutant were kind gifts from Dr. Sus-
ann Brady-Kalnay (Case Western). Full-length occludin was
provided by Alan Fanning (University of North Carolina,
Chapel Hill, NC). For adenovirus, the full-length cDNA of
DEP-1 WT or DEP-1 D/A was cloned into pENTR1D
(Invitrogen). The entry clone was recombined with the pAd/
CMV/V5 destination vector via LR clonase II. The Vira-
Power Adenviral expression vector (Invitrogen) was linear-
ized and then transfected into 293A cells via Lipofectamine
2000 to generate adenovirus encoding V5-tagged DEP-1WT
and DEP-1 D/A. The virus particles were used to infect
MDCK II cells. RNA interference oligos were ON-TARGET-
plus SMARTpool siRNA for DEP-1 or ON-TARGETplus
Control siRNA 1 (Dharmacon).
Mouse anti-occludin, rabbit anti-ZO-1, and mouse anti-
ZO-1 antibodies were purchased from Zymed Laboratories
Inc.. Mouse anti-human CD148 (DEP-1) antibody was pur-
chased from BIOSOURCE. GFP monoclonal antibody was
from Roche. Monoclonal antibodies to E-cadherin, p120-cate-
nin, and moesin were purchased from BD Bioscience, anti-Src
was purchased fromMillipore, AF-6 rabbit polyclonal was from
Novus Biological, and monoclonal PY-20 was purchased from
Santa Cruz Biotechnology.
GST Fusion Proteins
Expression of the fusion proteins in Escherichia coli was
induced with 100 M isopropyl -D-thiogalactopyranoside for
16 h at room temperature. Bacterial cells were lysed in buffer
containing 50 mM Tris (pH 7.6), 150 mM NaCl, 1% Triton
X-100, 5 mM MgCl2, 1 mM dithiothreitol, 10 g/ml each of
aprotinin and leupeptin, and 1 mM phenylmethylsulfonyl fluo-
ride and the fusion proteins were purified by incubation with
glutathione-Sepharose 4B beads (GE Healthcare) at 4 °C. Cata-
lytic activity of the fusion proteins was checked by PTP activity
assays using p-nitrophenyl phosphate (Sigma).
Occludin and ZO-1 Are Substrates of DEP-1
14998 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284 • NUMBER 22 • MAY 29, 2009
Substrate Trapping Pulldown
MCF10A cells were either left untreated or treated with 100
M pervanadate (phosphatase inhibitor) for 15 min prior to
lysis. Cells were rinsed twice in phosphate-buffered saline and
lysed in a modified RIPA buffer (1% Triton X-100, 0.5% deoxy-
cholate, 0.2% SDS, 150 mM NaCl, 20 mM Hepes, pH 7.4, 2 mM
EDTA, 10g/ml each aprotinin and leupeptin, and 1mMphen-
ylmethylsulfonyl fluoride). Insoluble material was removed by
centrifugation. MCF10A lysates (1 mg) were incubated with 10
g ofGSTproteins for 1 h at 4 °C unless otherwise noted. Beads
were washed in the modified RIPA buffer, resuspended in Lae-
mmli sample buffer, and analyzed by SDS-PAGE and Western
blotting on polyvinylidene difluoride membranes (Millipore).
To determine whether the substrates were binding DEP-1
D/A at the PTP active site, we tested the effect of orthovanadate
on complex formation. GST fusion proteins bound to glutathi-
one-Sepharose were preincubated in a Hepes lysis buffer (1%
Triton X-100, 150 mM NaCl, 20 mM Hepes, pH 7.5, 5 mM
MgCl2), with or without 2 mM orthovanadate. MCF10A cells
were treatedwith 100Mpervanadate for 15min and also lysed
in Hepes lysis buffer with or without 2 mM orthovanadate.
Lysates (500 g to 1 mg) were incubated with 2 g of GST-
DEP-1 or GST-DEP-1 D/A for 1.5 h at 4 °C. Beads were washed
in the Hepes lysis buffer, resuspended in Laemmli sample
buffer, and analyzed by SDS-PAGE and Western blotting on
polyvinylidene difluoride membranes. Because ZO-1 interac-
tion was difficult to detect with low concentrations of recom-
binant DEP-1 D/A, 50 g of GST-DEP-1 D/A was incubated
with lysates prepared with or without 10mM orthovanadate for
1.5 h at 4 °C to efficiently compete for the substrate binding.
Dephosphorylation Assays
MCF10A cells were treated with 100 M pervanadate for 15
min, washed twice with phosphate-buffered saline, and lysed in
the modified RIPA buffer plus 10 g/ml each aprotinin and
leupeptin, 1mMphenylmethylsulfonyl fluoride, and 5mM iodo-
acetic acid. After incubation of the lysates on ice for 10 min,
dithiothreitol was added at a final concentration of 10 mM for
another 10 min on ice to inactivate the iodoacetic acid. Lysates
were clarified and 500 g of total cell lysate was incubated with
1 g of glutathione-Sepharose bound GST-PTPs for 20 min at
room temperature. The phosphatases were removed by centrif-
ugation, orthovanadate was added to the samples, and occludin
or ZO-1 was immunoprecipitated for 2 h at 4 °C. Beads were
washed in the lysis buffer and processed for SDS-PAGE. The
immune complexes were analyzed by Western blotting using
PY-20 antibody, occludin monoclonal antibody, or ZO-1 poly-
clonal antibody. Alternatively, HEK 293 cells were transfected
with occludin and the pMT2.DEP-1 constructs for 48 h and
lysed directly in hot 2 SDS gel sample buffer (200mMTris, pH
6.8, 20% glycerol, 4% SDS, 5% 2-mercaptoethanol), and boiled
for 10min. Samples were then diluted 20-fold with phospho-IP
buffer (150 mMNaCl, 20 mM Tris, pH 7.6, 1% Triton X-100, 1%
sodium deoxycholate, 1 mM sodium orthovanadate, 10 g/ml
leupeptin, 10 g/ml aprotinin) to a final concentration of 0.1%
SDS. One g of occludin antibody and protein G-Sepharose
were added and samples were incubated for 4 h at 4 °C. Samples
were then washed in Tris-buffered saline and analyzed by
Western blot using anti-PY20 antibody. Membranes were
stripped and reprobed with an antibody to occludin for a load-
ing control. For ZO-1 in vivo dephosphorylation, A431 cells
were transfected with pMT2 constructs for empty vector, wild
type, and DEP-1 C/S mutant. Cells were serum starved in
DMEM  0.5% bovine serum albumin for 4 h and EGF was
added to a final concentration of 100 ng/ml for varying times.
Following treatment, cells were washed with phosphate-buff-
ered saline and lysed in themodified RIPA buffer containing 10
g/ml each aprotinin and leupeptin, 1 mM phenylmethylsulfo-
nyl fluoride, and 1mM sodiumorthovanadate. ZO-1was immu-
noprecipitated overnight from lysates using a rabbit polyclonal
anti-ZO-1 antibody (Zymed Laboratories Inc.). Immunopre-
cipitateswerewashed and analyzed by SDS-PAGEandWestern
blottingwith PY-20 antibody and reprobedwith the ZO-1 poly-
clonal antibody for loading control.
Immunofluorescence
MDCK II cells were fixed with 3.7% formaldehyde in phos-
phate-buffered saline and permeabilized in 0.5% Triton X-100.
Occludin was visualized with anti-occludin monoclonal anti-
body (Zymed Laboratories Inc.) at 1:200 for 45 min at 37 °C
followed by an anti-mouse Alexa 594-conjugated secondary
antibody. Images were recorded with a Zeiss LSM510 confocal
microscope.
Calcium Switch Experiments
MDCK II cells were plated at confluent density (4  105
cells/cm2) onto Transwell filters (0.4 m pore, 12-mm diame-
ter; Corning). Growth media was removed from cells 3–4 h
after plating and replaced with DMEM containing low calcium
(5 M) overnight (16 h). Disruption of cell-cell junctions was
confirmed byTERmeasurements of only 2 ohms/cm2. Junction
reassembly was induced with the addition of calcium contain-
ing DMEM (1.8 mM CaCl2) for the indicated length of time.
Permeability Assays
TER—MDCK II cells were infected with pAd/CMV/GFP,
pAd/CMV/V5-DEP-1WT, or pAd/CMV/V5-DEP-1 D/A. 24 h
later, cells were plated at confluent density (4  105 cells/
cm2) onto Transwell filters (0.4 m pore, 12-mm diameter;
Corning) and cultured for 4 days, withmedia replacement daily.
TER was measured using an Endohm-12 Transwell chamber
connected to an EVOMvoltohmeter (World Precision) accord-
ing to the manufacturer’s instructions. For calcium switch
experiments, TER was measured at the indicated time points
following re-addition of calcium containing media. The resist-
ance of the filter was subtracted from all readings.
FITC-Dextran Flux—MDCK II cells were infected with
DEP-1WT, DEP-1 D/A, or GFP control adenovirus and plated
the same as for the TER measurements above. For the calcium
switch, calcium containing DMEMwas added to the chambers
for the indicated length of time; 1 ml in the outer chamber and
250 l in the inner chamber. 10-kDa FITC-dextran (Molecular
Probes) was added to the top chamber in a volume of 50 l at a
final concentration of 1mg/ml. After 1 h, a samplewas removed
from the basolateral (bottom) compartments and read in a flu-
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orometer (FluroStar Optima, BMGLABTECH) (excitation 485
nm, emission 520 nm).
Knockdown of DEP-1
MCF10Acellswere transfectedwith siRNAoligosat a final con-
centration of 25 nM for 72 h and lysed in themodified RIPAbuffer
with protease inhibitors. Alternatively, cells were transfected and
24 h later plated on Transwell filters (0.4mpore, 12mmdiame-
ter; Corning) for an additional 48 h and TERwasmeasured.
Statistics
Comparison between two groups was made by the Student’s
t test for unpaired data. Comparisons of the means of the more
than two groups weremade by single factor analysis of variance
followed by the Fisher’s LSD post hoc test.
RESULTS
Identification of DEP-1 Substrates at the Tight Junction—Ty-
rosine phosphorylation of AJ proteins compromises the integ-
rity of the cadherin-catenin com-
plex as well as the junctional
integrity of cell monolayers (22-
24). Protein-tyrosine phosphatases,
such as DEP-1, are capable of
dephosphorylating AJ proteins (27,
40). Tight junction proteins can also
be regulated by tyrosine phospho-
rylation and we sought to identify
whether tight junction proteins are
potential substrates of the phospha-
tase DEP-1. To accomplish this, we
used a substrate-trapping mutant of
DEP-1 in which the conserved
aspartic acid in theWPD loop of the
catalytic domain is mutated to an
alanine (D1205A), which traps
the substrate within the catalytic
domain of the phosphatase (43).
Cytoplasmic domains ofDEP-1wild
type (DEP-1WT) and the substrate-
trapping mutant (DEP-1 D/A) were
expressed as GST fusion proteins
and used in pulldown assays to iden-
tify potential physiological sub-
strates of DEP-1. MCF10A cells
were treated with pervanadate to
generate a pool of tyrosine-phos-
phorylated proteins. As seen in Fig.
1A, only the substrate-trapping
mutant (DEP-1 D/A) was able to
bind to phosphorylated proteins.
Interestingly, we noticed a band at
64 kDa that is able to bind DEP
D/A without the addition of per-
vanadate. It is possible that this pro-
tein is the 64-kDa serine/threonine
kinase found constitutively associ-
ated with DEP-1 (44).
DEP-1 is known to localize and interact with proteins located
at adherens junctions (27, 40), but it is not known whether
DEP-1 or any other PTPs are able to act on tight junction pro-
teins. To identify potential substrates at the tight junction, we
again performed the GST-DEP-1 pulldown assay and probed
with antibodies to known junctional proteins. The tight junc-
tion proteins occludin and ZO-1 bound to DEP-1 D/A in a
phosphorylation-dependent manner (Fig. 1B). Claudin 1 and 3
were also blotted for and did not bind DEP-1 D/A in our exper-
iments (data not shown). The protein-tyrosine kinase Src and
p120-catenin, both known substrates of DEP-1 (27, 45), were
also able to bind to DEP-1 D/A (Fig. 1B). In contrast, no inter-
actionwas detected betweenDEP-1 and the junctional proteins
E-cadherin and AF-6, or the cytoskeletal protein moesin (Fig.
1B).We can detect an interaction between occludin and DEP-1
D/A with as little as 5 g of the fusion protein and the interac-
tion increases in a dose-dependent manner (Fig. 1C). However,
20 g of DEP-1 D/A is required to detect ZO-1 interaction
perhaps indicating a difference in binding affinity (Fig. 1C).
FIGURE 1. The substrate-trapping mutant of DEP-1 binds tight junction proteins in a tyrosine phospho-
rylation-dependent manner. MCF10A cells were either left untreated () or were treated () with pervana-
date prior to lysis. GST alone, GST-DEP-1 WT, or GST-DEP-1 D/A fusion proteins were incubated with cell lysates and
protein complexes were analyzed by SDS-PAGE and immunoblotting with: A, phosphotyrosine antibody (PY-20); or
B, antibodies to ZO-1, occludin, Src, p120-catenin, E-cadherin, AF-6, and moesin. In the lower panel of A, the mem-
brane was Coomassie stained to demonstrate equivalent amounts of GST PTPs were used. For the ZO-1 experiment
in B, we used 100 g of GST protein due to the reduced affinity for binding (see C). C, MCF10A cells were treated as
described above. Lysates were incubated with the indicated amounts of GST proteins and protein complexes were
analyzed by SDS-PAGE and immunoblotting with antibodies to ZO-1 and occludin. D, effects of orthovanadate on
the interaction between occludin or ZO-1 and DEP-1 D/A. MCF10A cells were treated with pervanadate and lysed
with () or without () sodium orthovanadate. GST-DEP-1 fusion proteins were preincubated with () or without
() sodium orthovanadate and added to the lysates. Protein complexes were analyzed by SDS-PAGE and immuno-
blotting with occludin or ZO-1 antibodies. The membranes were stained with Coomassie Blue to confirm that equal
amounts of GST-DEP-1 proteins were used.
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Future experiments will need to be performed to further
explore this possibility.
To determine whether ZO-1 and occludin bind to the cata-
lytic site of DEP-1, the GST-DEP-1 proteins were preincubated
with orthovanadate and tested for their ability to bind to the
tight junction proteins. Orthovanadate is a competitive inhibi-
tor that blocks the active site of DEP-1 and prevents substrate
binding as well as enzymatic activity (46). In the presence of
orthovanadate, the interaction
between ZO-1 or occludin and
DEP-1 D/A was inhibited (Fig. 1D),
indicating that both proteins bind
the active site of the catalytic
domain of DEP-1. These results
suggest that DEP-1 specifically
interacts with a small subset of junc-
tional proteins that includes ZO-1
and occludin.
DEP-1 Dephosphorylates Occlu-
din and ZO-1—Having shown that
occludin and ZO-1 can bind to
DEP-1, we tested whether they are
in fact substrates of the phospha-
tase. First, MCF10A cells were
treated with pervanadate to induce
phosphorylation of occludin and
ZO-1, and then lysates were incu-
bated with GST, GST-DEP-1 WT,
and either the substrate-trapping
mutant GST-DEP-1 D/A or the cat-
alytically inactive mutant GST-
DEP-1 C/S. ZO-1 or occludin were
immunoprecipitated from the ly-
sates and phosphotyrosine levels
were measured by blotting with an
anti-phosphotyrosine antibody. As
shown in Fig. 2, A and B, wild type
DEP-1 dephosphorylated both
occludin and ZO-1, whereas GST
and DEP-1 D/A or GST and DEP-1
C/S did not. Note that the extensive
band shift of immunoprecipitated
occludin incubated with DEP-1WT
is consistent with dephosphoryla-
tion of occludin by the PTP. These
results confirm that occludin and
ZO-1 are in fact substrates of DEP-1
in vitro. Next, we asked whether
DEP-1 can dephosphorylate occlu-
din when both are expressed
together in cells. Full-length DEP-1
mammalian expression constructs
(pMT2.DEP-1 WT, pMT2.DEP-1
D/A, or pMT2.DEP-1C/S) or empty
vector were co-expressed with
occludin in HEK 293 cells, occludin
was immunoprecipitated and phos-
photyrosine levels were analyzed
(Fig. 2C). In cells overexpressingDEP-1WTphosphorylation of
occludin was dramatically reduced compared with cells
expressing empty vector, DEP-1 D/A, or DEP-1 C/S (Fig. 2C).
We also tested the ability of DEP-1 to dephosphorylate ZO-1
in vivo. However, we had difficulty immunoprecipitating ZO-1
with the samemethods used for occludin. Therefore, a different
experimental system was used. EGF stimulation has been
shown to phosphorylate ZO-1 in A431 cells (47). We treated
FIGURE 2. DEP-1 dephosphorylates occludin and ZO-1. A and B, in vitro dephosphorylation assay. MCF10A
cells were treated with pervanadate prior to lysis. Lysates were incubated with glutathione-Sepharose bound
GST or GST-DEP-1 fusion proteins, followed by the removal of the fusion proteins by centrifugation. ZO-1 (A)
and occludin (B) were immunoprecipitated from the lysate supernatant. Immunocomplexes were analyzed by
SDS-PAGE and immunoblotted with PY-20 antibody and reprobed with occludin or ZO-1 antibodies for the
loading control. C–E, in vivo dephosphorylation assay. C, HEK 293 cells were transfected with occludin and
empty pMT2 vector, pMT2.DEP-1 WT, pMT2.DEP-1 D/A, or pMT2.DEP-1 C/S. Cells were lysed in sample buffer,
diluted in phospho-IP buffer, and immunoprecipitated (IP) with an anti-occludin antibody. Samples were
analyzed by SDS-PAGE and immunoblotted with anti-phosphotyrosine antibody or anti-occludin antibody.
Lysates are also shown to demonstrate the level of DEP-1 overexpression. D, A431 cells were serum starved and
then treated with EGF for 0, 1, 2, 5, and 10 min. Cells were lysed and immunoprecipitated with an anti-ZO-1
antibody. Immunoprecipitates were analyzed by SDS-PAGE and immunoblotted with a PY-20 or ZO-1 anti-
body. Arrow indicates the band for ZO-1. E, A431 cells were transfected with pMT2 vector, pMT2.DEP-1 WT, or
pMT2.DEP-1 C/S. 24 h later cells were serum starved and left untreated (0) or treated with EGF for 5 min. Cells
were processed as in D. Lysates are shown to demonstrate the level of DEP-1 expression in the transfected cells.
WB, Western blot.
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A431 cells with EGF for varying time points and saw an increase
in tyrosine phosphorylation of endogenous ZO-1, which
peaked at 2–5 min (Fig. 2D). We transfected A431 cells with
empty vector, pMT2.DEP-1 WT, or pMT2.DEP-1 C/S and left
cells either untreated or treated with EGF for 5 min (Fig. 2E).
The expression of DEP-1 WT in A431 cells induced dephos-
phorylation of ZO-1 following EGF treatment compared with
the expression of empty vector or DEP-1 C/S (Fig. 2E). These
combined experiments suggest that both ZO-1 and occludin
are substrates of DEP-1 and that DEP-1 catalytic activity is
required for the dephosphorylation of ZO-1 and occludin
in vivo.
Occludin and ZO-1 Interaction Is Specific to DEP-1—We
wanted to determine whether the interaction of DEP-1 with
occludin and ZO-1 was specific or if these proteins were sub-
strates for additional PTPs. Lysates of untreated or pervana-
date-treated MCF10A cells were incubated with GST fusion
proteins of substrate-trapping mutants of DEP-1 (GST-DEP-1
D/A), PTP-PEST (GST-PTP-PEST D/A), and other junctional
PTPs including Shp2 (GST-Shp2 C/S) and PTP (GST-PTP
D/A).DEP-1D/Awas the only PTPof those tested thatwas able
to interact with ZO-1 and occludin, and it did so in a tyrosine
phosphorylation-dependent manner (Fig. 3, A and B). To con-
firm that the substrate-trapping mutants were functional, pull
downs were blotted with an anti-phosphotyrosine antibody,
and all were found to bind tyrosine-phosphorylated proteins
(data not shown). In addition, membranes were stained with
Coomassie Blue to verify the use of equal amounts of PTP
fusion proteins (Fig. 3, A and B). We also confirmed that other
PTPs were comparatively inefficient at dephosphorylating
occludin and ZO-1. MCF10A cells were treated with pervana-
date to induce protein phosphorylation and incubated with
wild type GST fusion proteins of DEP-1, PTP-PEST, PTP, and
PTP. Following incubation, fusion proteins were removed by
centrifugation, and then occludin and ZO-1 were immunopre-
cipitated and the phosphotyrosine levels analyzed. As shown in
Fig. 3, C and D, GST-WT DEP-1 was able to completely
dephosphorylate occludin and ZO-1, whereas the other PTPs
had little effect. Again, notice the decrease in molecular weight
of the occludin that accompanied dephosphorylation by DEP-1
WT (Fig. 3C). These results suggest that occludin and ZO-1 are
specific substrates of DEP-1 and not other PTPs tested.
DEP-1 andOccludinCo-localize atAreas ofCell-CellContact—
Previous studies have shown thatDEP-1 localizes at points of cell-
cell contact as well as along the apical plasmamembrane (27, 42).
We examined the extent of DEP-1 and occludin co-localization at
tight junctions. MDCK II cells were transfected with GFP or
DEP-1 WT-GFP and were stained with anti-occludin antibodies
to visualize endogenous occludin at tight junctions. As shown in
Fig.4, therewassignificantcolocalizationofDEP-1andoccludinat
sites of cell-cell contact.
DEP-1 Expression Enhances Barrier Function as Junctions
Reassemble—We next determined whether our previously
observed dephosphorylation of occludin and ZO-1 had func-
tional consequences with respect to tight junction physiology.
MDCK II cells were infected with GFP, DEP-1 WT, or DEP-1
D/A adenovirus, plated onto transwell filters, and TER of the
stable junctions was measured 4 days post plating. In epithelial
cells overexpressing DEP-1 we saw a small but significant
increase in TER compared with the GFP control (100% versus
109  2%) (p  0.05) (data not shown), supporting the hypoth-
esis that expression of DEP-1 can decrease the permeability of
steady state tight junctions albeit very slightly.
To better address the ability of DEP-1 to regulate tight junc-
tion function, we measured the permeability of epithelial
monolayers during junctional reassembly following a calcium
switch (48, 49). First we looked at FITC-dextran flux across the
monolayers. MDCK II cells were infected with GFP, DEP-1
WT, or DEP-1 D/A adenovirus and plated on transwell filters.
After cells had adhered, growth media was replaced with low
calcium media overnight (5 M). Normal calcium-containing
media (1.8 mM) was then added to the transwells and the ability
of FITC-dextran to pass across themonolayer was assessed at 0,
6, 12, 24, and 48 h. The amount of FITC-dextran that crossed
themonolayers was significantly reduced as junctions reassem-
bled (Fig. 5A). At early stages of junction reassembly (6 h), the
presence of additional DEP-1WT decreased permeability indi-
cated by the further decrease of FITC-dextran flux compared
with GFP and DEP-1 D/A control cells (Fig. 5A). After 12 and
FIGURE 3. Occludin and ZO-1 are specific substrates of DEP-1. A and B,
substrate-trapping mutants of different PTPs. MCF10A cells were either left
untreated () or were treated () with pervanadate prior to lysis. Lysates
were incubated with the GST fusion proteins of the substrate-trapping
mutants of the indicated cytoplasmic and receptor PTPs. Protein complexes
were analyzed by SDS-PAGE and immunoblotted for: A, ZO-1; and B, occludin.
Membranes were stained with Coomassie Blue to confirm that equal amount
of PTP fusion proteins were used. C and D, in vitro dephosphorylation assay.
MCF10A cells were treated with pervanadate prior to lysis. Lysates were incu-
bated with GST or wild type GST-PTP fusion proteins bound to glutathione-
Sepharose, the fusion proteins were removed by centrifugation and occludin
(C) or ZO-1 (D) were immunoprecipitated from the lysates. Immunocom-
plexes were analyzed by SDS-PAGE and immunoblotted with PY-20, occludin,
or ZO-1 antibodies. WB, Western blot.
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24 h in calcium-containing media, the permeability between
control and DEP-1 expressing cells was not significantly differ-
ent (Fig. 5A). In identical experiments, barrier function was
measured by TER following the calcium switch. Monolayers
overexpressing DEP-1 WT have higher TER than GFP and
DEP-1 D/A controls at 6, 12, and 24 h of junction reassembly
(Fig. 5B). The differences between DEP-1 D/A and DEP-1 WT
at 12 and 24 h are statistically significant. Together the TER and
FITC-dextran data reveal that expression of DEP-1 WT
enhances the barrier function of epithelial junctions during
reassembly. Thus, the presence of DEP-1 is particularly impor-
tant at the dynamic stages of junctional assembly.
Reduction of DEP-1 Protein Expression Increases Epithelial
Permeability—With an increase in DEP-1 levels resulting in
strengthened barrier function, conversely we tested whether
loss of DEP-1 expression reduced junctional integrity. We
transfected MCF10A cells with siRNA oligos targeting DEP-1
or with non-targeting (NT) control oligos and saw reduced
expression of DEP-1 after 72 h (Fig. 6A). MCF10A cells were
plated onto transwell filters 24 h post-transfection and cultured
for an additional 48 h before TER measurements were taken.
The loss of DEP-1 expression in MCF10A cells reduced the
electrical resistance of themonolayer by 13.1% (1%) (Fig. 6B).
DISCUSSION
Cell-cell junctions can be regulated through reversible tyro-
sine phosphorylation. Tyrosine phosphorylation of junction
proteins has been shown either to promote the dissociation of
protein complexes at the junction (22–24, 50) or to promote the
internalization and degradation of junctional proteins (51).
Whereas most work in this area has focused on the tyrosine
kinases that act on junctional proteins, it is equally important to
identify the PTPs and their targets within cell-cell junctions.
Here we show for the first time that the prominent tight junc-
tion proteins, occludin andZO-1, interact with and are dephos-
phorylated by the PTP DEP-1.
Experimentally increasing the levels
of DEP-1 reduced the permeability
of epithelial monolayers during
the early stages of junction assem-
bly. Conversely, reducing DEP-1
protein levels increased perme-
ability of monolayers.
Similar to the adherens junctions,
tyrosine phosphorylation has been
correlated with the dissociation of
tight junction components, pro-
moting the detachment of ZO-1
from occludin (12, 19, 52–54). This
increased tyrosine phosphorylation
of tight junction components is par-
alleled by increased epithelial per-
meability. Because DEP-1 has previ-
ously been localized to regions of
cell-cell contact (27, 42), we exam-
ined whether the phosphorylation
of tight junction proteins was regu-
lated by this PTP.We found that the
catalytically dead trapping mutant of DEP-1 binds to phospho-
rylated forms of occludin and ZO-1 and that catalytically active
DEP-1 dephosphorylates these proteins. Previous work has
shown thatDEP-1 interacts with and acts on the adherens junc-
tion proteins p120 catenin and -catenin (27, 40), and we have
confirmed these interactions (Fig. 1B and data not shown).
However, we found that DEP-1 does not bind all tyrosine-phos-
phorylated junctional proteins such as AF-6 (Fig. 1B). It is strik-
ing that several PTPs are concentrated within epithelial junc-
tions (55) and it is likely that there is some redundancy with
respect to their targets. We were surprised to find that two
junctional PTPs, PTP and SHP-2, did not significantly inter-
act with or dephosphorylate occludin and ZO-1 (Fig. 3). This
result suggests that the different PTPs within cell-cell junctions
have specific targets and that they may regulate distinct signal-
ing pathways. These pathways may either be initiated within
junctions in response to cell-cell interactions or be triggered by
a stimulus such as growth factors or oxidative stress to regulate
junction stability, strength, and permeability.
Having found that DEP-1 dephosphorylates occludin and
ZO-1, we explored the effect of DEP-1 on tight junction func-
tion in epithelial cells. Mature junctions are thought to exist in
a tyrosine-dephosphorylated state, with increased tyrosine
phosphorylation leading to increased junction disassembly, and
increased paracellular permeability (16, 17). Thus, dephospho-
rylation of occludin, as well as other junctional proteins, is
believed to increase the barrier function of the junction. Our
overexpression of DEP-1 in epithelial cells increased TER (data
not shown), a measure of increased barrier properties of the
junctions, consistent with phosphorylation regulating the per-
meability of tight junctions. Although the difference was subtle
(5–10% increase), it was reproducible and statistically signifi-
cant. We suspect the small effect on TER is due to the fact that
the cells had been confluent for several days. At this point, the
junctions have reduced dynamics and the level of tyrosine
FIGURE 4. DEP-1 localizes to areas of cell-cell contact. MDCK II cells were transfected with pEGFP or pEGFP-
DEP-1 (a and d) and stained for occludin (b and e). Merged images show colocalization in yellow (c and f). Scale
bar  10 m.
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phosphorylation is very low (essentially undetectable). Because
tyrosine phosphorylation is elevated during disassembly/as-
sembly of junctions, this led us to explore the effect DEP-1 had
on junctional permeability as the junctions were assembling.
Using the established calcium switch technique (49, 56) to
modulate cell-cell adhesion, we measured the permeability of
epithelial junctions with both TER and FITC-dextran flux over
a time course of junction reassembly. As shown in Fig. 5A, as
junctions reassemble after calcium addition, the permeability
decreases over time. Importantly, when comparing the perme-
ability of GFP-or DEP-1 D/A-expressing versus DEP-1 WT-
expressing cells at 6 h following calcium restoration, the pres-
ence of DEP-1 WT significantly reduces the permeability of
FITC-dextran flux, suggesting that these junctions reassembled
more rapidly (Fig. 5A). By 12 and 24 h the difference in perme-
ability between control cells and
DEP-1-expressing cells was not sta-
tistically significant (Fig. 5A). The
TER data mimics the FITC-dextran
flux experiment (Fig. 5B) in that the
cells overexpressing DEP-1 WT
have increased TER compared with
GFP and DEP-1 D/A expressing
cells at earlier time points during
reassembly. However, the TER
remains higher through the 24-h
time point, leveling off at 48 h,
although the FITC-dextran flux lev-
els were similar by 12 h of reassem-
bly. This difference may reflect the
difference between measuring the
permeability of ions versus macro-
molecules in epithelial cells. Knock-
down of DEP-1 protein levels in epi-
thelial cells compromised barrier
function when compared with con-
trol cells. The reduction in TER was
small but statistically significant.
This phenotype is mirrored in the
DEP-1 knock-out mice, which are
fertile, viable, and show no gross
anatomical alterations (57). This
may be due to other PTPs that can
compensate at some level in diverse
signaling pathways. In future stud-
ies it would be interesting to exam-
ine whether protein levels of other
PTPs increase in DEP-1 knockdown
cells. In addition, it is also possible
that examining the effect of loss of
DEP-1 in cells with extremely tight
junctions, such as brain endothelial
cells, would produce a more dra-
matic effect in permeability. Over-
all, our results suggest a model in
which DEP-1 is a receptor PTP that
localizes to cell-cell junctions, and is
able to regulate phosphorylation
levels of junctional proteins. In this way, it aids in the reforma-
tion of the tight junction and enhances barrier function of epi-
thelial junctions during calcium-induced reassembly.
The identification ofDEP-1 substrates at the tight junction in
this paper strengthens the hypothesis that DEP-1 localizes to
and dephosphorylates junction proteins, contributing to the
regulation of junctional permeability. A growing body of liter-
ature suggests that tyrosine phosphorylation of TJ proteinsmay
play a key role in regulating epithelial tight junctions; however,
the role of tyrosine phosphatases in this regulation has not been
investigated. Increases in tyrosine phosphorylation of occludin
and ZO-1 disrupts their association with each other and
reduces their localization at junctions (12, 19), as well as
decreases transepithelial electrical resistance of monolayers
(16, 17). Recently, twoC-terminal tyrosine residues of occludin,
FIGURE 5. Expression of DEP-1 enhances barrier function as junctions reassemble. MDCK II cells were
infected with GFP, DEP-1 WT, or DEP-1 D/A adenovirus and grown on filters as confluent monolayers. Cells were
incubated in low calcium media for 16 h to completely disrupt junctions (as measured by TER), and then
transwell filters were switched to normal calcium media. A, at varying time points after the addition of calcium
media, 10-kDa FITC-dextran was added to the top chamber of the transwell filter and allowed to cross the cell
monolayer for 1 h. Values across all times were normalized to the amount of FITC-dextran flux that crossed the
GFP control cell monolayer at 0 h. Data shown are the ratio  S.E. for samples in triplicate. Double asterisk
indicates significance values at p  0.01, and single asterisk indicates significance values at p  0.05. The graph
shows a representative experiment. B, TER was measured over 72 h after the calcium switch. Data are expressed
as mean  S.E. of filters in triplicate. This graph shows a representative experiment. Double asterisk indicates
that the value is significantly (p  0.01) different from the corresponding value for DEP-1 D/A. Single asterisk
indicates that the value is significantly (p  0.05) different from the corresponding value for DEP-1 D/A.
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Tyr-398 and Tyr-402, have been identified as Src-induced
phosphorylation sites (21). This study found that phosphoryla-
tion of these residues prevented ZO-1 binding to occludin in
vivo, building on the in vitro study performed previously (12).
The crystal structure of occludin demonstrates that the coiled-
coiled region locatedC-terminal to these residues is also impor-
tant for ZO-1 interaction (58). Tyrosines in this regionmay also
be sites for potential phosphoregulation of ZO-1-occludin
interactions. With the identification of specific tyrosine resi-
dues that are regulated by phosphorylation, it would be inter-
esting to test whether DEP-1 is able to dephosphorylate Tyr-
398 and Tyr-402, enhancing the interaction of occludin and
ZO-1. Development of phosphospecific antibodies to these
newly identified residues would aid in determining how phos-
phorylation at these sitesmay be involved in signaling pathways
downstream of certain stimuli such as growth factors and oxi-
dative stress.
Previous studies have implicated DEP-1 as a factor in the
deregulation of growth and differentiation in numerous
types of cancers (59–61), and led to the proposal that DEP-1
is a tumor suppressor. The action of DEP-1 on both adherens
and tight junctions suggests another means by which DEP-1
may protect cells from oncogenic transformation andmetas-
tasis; controlling the strength and stability of cell-cell inter-
actions. Diminished interaction of a cell with its neighbors is
a hallmark of cancer and particularly associated with tumor
invasion and metastasis. In future work, we hope to examine
whether the relationship of DEP-1 with occludin and ZO-1 is
changed in specific epithelial tumors. The continued identi-
fication of junctional substrates of DEP-1 will aid in further-
ing our understanding of the role of this PTP in diseases such
as cancer.
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